Latest news
FDA Approves Palbociclib for HR+, HER2+ Breast Cancer Maintenance - The American Journal of Managed CareThe American Journal of Managed Care · Fri, 07 Aug 2026 18:55:26 GMTDr Brufsky on the FDA Approval of Gedatolisib Plus Fulvestrant ± Palbociclib in PIK3CA Wild-Type Breast Cancer - OncLiveOncLive · Fri, 07 Aug 2026 03:24:28 GMTDr Barot on the FDA Approval of Palbociclib/Trastuzumab ± Pertuzumab in HER2+ Breast Cancer - OncLiveOncLive · Fri, 31 Jul 2026 03:40:00 GMT